JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 166 filers reported holding JUNO THERAPEUTICS INC in Q4 2016. The put-call ratio across all filers is 1.25 and the average weighting 1.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2017 | $482,140,000 | -0.9% | 10,547,788 | -2.8% | 0.60% | -2.8% |
Q3 2017 | $486,659,000 | +45.7% | 10,848,400 | -2.9% | 0.62% | +37.2% |
Q2 2017 | $333,964,000 | +34.4% | 11,173,129 | -0.2% | 0.45% | +24.0% |
Q1 2017 | $248,481,000 | +19.2% | 11,197,863 | +1.2% | 0.36% | +5.5% |
Q4 2016 | $208,518,000 | -36.0% | 11,061,955 | +2.0% | 0.34% | -32.6% |
Q3 2016 | $325,574,000 | -21.9% | 10,848,851 | +0.0% | 0.51% | -31.6% |
Q2 2016 | $416,831,000 | +0.2% | 10,843,672 | -0.7% | 0.74% | +1.6% |
Q1 2016 | $415,880,000 | +3277.8% | 10,918,377 | +3799.4% | 0.73% | +3385.7% |
Q4 2015 | $12,312,000 | – | 280,000 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Biomark Capital Management Co. LLC | 1,864,174 | $83,627,000 | 94.97% |
Crestline Management, LP | 9,348,799 | $419,387,000 | 58.30% |
Omega Fund Management, LLC | 1,074,612 | $48,207,000 | 27.27% |
PECONIC PARTNERS LLC | 570,000 | $25,570,000 | 4.12% |
SIB LLC | 100,000 | $4,486,000 | 3.22% |
Cormorant Asset Management, LP | 375,000 | $16,823,000 | 2.97% |
BB BIOTECH AG | 2,055,000 | $92,187,000 | 2.55% |
Clarius Group, LLC | 117,896 | $5,289,000 | 2.23% |
Monashee Investment Management LLC | 122,000 | $5,473,000 | 2.07% |
Iguana Healthcare Management, LLC | 150,000 | $6,730,000 | 1.86% |